Kunihiro Odagiri
Nagoya, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab.
Journal: Anticancer research
Published: January 23, 2026
Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.
Journal: Cancer medicine
Published: January 14, 2026
Integrating pharmacokinetic modeling and wearable-derived physiological data to assess pain intensity in patients with advanced urologic cancer.
Journal: Japanese journal of clinical oncology
Published: October 28, 2025
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.
Journal: Cancer medicine
Published: June 26, 2025
Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study.
Journal: The oncologist
Published: April 04, 2025
Effect of Pembrolizumab on Lymph Node Dissection in Patients Who Experienced Bladder Cancer Recurrence Following Radical Cystectomy.
Journal: In vivo (Athens, Greece)
Published: April 02, 2025
Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy.
Journal: Cancer diagnosis & prognosis
Published: March 25, 2024
Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Journal: Asia-Pacific journal of clinical oncology
Published: November 25, 2023
Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Journal: Cancer medicine
Published: August 28, 2023
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: September 24, 2022
GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma.
Journal: Oncology
Published: August 16, 2022
Showing 1-11 of 11
Last Updated: 09/26/2026